Skip to main content
. 2020 Oct 13;12(10):2948. doi: 10.3390/cancers12102948

Figure 1.

Figure 1

Ramucirumab Mesothelioma clinical trial (RAMES) study design. MPM, malignant pleural mesothelioma, PD, progressive disease, TTP, time to progression, OS, overall survival, PFS, progression-free survival, ORR, overall response rate, QoL, quality of life.